OPINION: This article contains commentary which may reflect the author's opinion
Democrat Joe Biden is misleading American parents about the availability of baby food and is seemingly unconcerned about the panic-inducing fear created in the hearts and souls of parents trying to feed their infant children.
Before the age of 12 months old, infants have very specific nutritional and digestive needs. Children under the age of 1 year old can not be fed just any kind of food because of the development of their system, and with the decreased use of natural breastfeeding, many American parents are dependent on Baby Formula.
So-like the third-world nation, the United States has become- under Biden and the Democrats- parents who are now in a race to scrounge up fleeting supplies of food, and manufacturers face crisis after crisis getting new supplies out to the public.
Because we have too few manufacturers of Baby Formula.
To compound the problems for American parents are being exposed to a reckless and bloated Federal agency, the Federal Food and Drug Administration, which is led by more Democrats, who are hiding behind their massive regulations and which keeps government workers in business- but prevents progress for getting work done, business flowing smoothly and supplies out to starving babies.
One of the few US Baby Formula manufacturers, Abbott, had to close down- as a worldwide shortage and supply chain colluded, and has left few options for American parents. And the Biden administration seems helpless to fix any of the problems.
In fact, on Monday afternoon, a Biden administration official admitted that he’s known about the looming formula shortage since last year and left parents unprepared for the crisis.
The Daily Mail reported on the Biden Baby Food drama:
Abbott baby formula factory claims the FDA HASN’T given it the greenlight to restart production despite agency claiming it could be up and running in two weeks. The Abbott Laboratories factory has reached a consent decree with the FDA, which is an important step towards reopening its Sturgis, Michigan plant, they reported.
The company says it could reopen in as few as two weeks after it gets approval from the courts, which must now approve the consent decree; however, the FDA has yet to give them the authority to resume operations.
When asked about a timeframe for reopening the plant, FDA Commissioner Robert Califf said: ‘We all know the treachery of giving exact timeframes.’
He reiterated he doesn’t expect the FDA to delay Abbott’s reopening. Frank Yiannas, an FDA official, said it is ‘totally reasonable and likely to happen’ that the plant would reopen and have products to consumers in 10 weeks.
Abbott’s CEO described the consent decree as ‘a major step toward re-opening our Sturgis facility so we can ease the nationwide formula shortage’.
The factory closed in February after the FDA recorded multiple health violations and two babies died after consuming their formula.
Abbott has emphasized that there is ‘no conclusive evidence to link Abbott’s formulas to these infant illnesses’.
Frank Yiannas, Deputy Commissioner for Food and Policy Response, weighed into the conversation, offering another tiptoed response on timing.
‘When we went in to do the inspection at the time of the inspection, Abbott voluntarily ceased production and we issued our inspection report,’ he said. ‘Abbott has stated in the public domain that they have already been making adjustments and corrections to their facility and that’s the timeline they’re projecting – two weeks to be back up in operations and another six to eight weeks for their products to start hitting store shelves.
‘We think that’s totally reasonable and likely to happen.’
The FDA leaders also addressed the consent decree, which was filed on Monday in the U.S. District Court for the Western District of Michigan and is decree is still subject to court approval.
Califf said he doesn’t expect the FDA to delay Abbott’s reopening.
‘In terms of a consent decree, it does mandate that we approve every step but it is in real time, including independent consultants who are brought in to oversee the process,’ the commissioner explained. ‘I don’t expect delays on the FDAs part on this unless we see a problem that needs to be dealt with.
Yiannas stated the agency would review Abbott’s ‘corrective action plans’ and also echoed Califf’s response, saying: ‘We don’t believe the FDA will be a hindrance in getting them back up and running.’
Abbott told DailyMail.com on Monday the facility has been working on corrective actions since the FDA’s inspection earlier this year. The company claims it submitted its corrective action plan to the FDA on April 8.
‘Even before its formal response, Abbott had begun working to implement improvements and take corrective action,’ a spokesperson said. ‘Some of these actions included reviewing and updating education, training and safety procedures for both employees and visitors, as well as updating protocols regarding water, cleaning and maintenance procedures at the facility.
‘Abbott immediately implemented corrections to address the items that the FDA raised in its observations provided at the conclusion of the inspection. The company has also been making upgrades to the plant.’
Despite these actions, it still remains unclear when the agency will allow the agency to resume normal operations.
‘Once the FDA confirms the initial requirements for start-up have been met, Abbott could restart the site within two weeks,’ the manufacturer reiterated. ‘The company would begin production of EleCare, Alimentum and metabolic formulas first and then begin production of Similac and other formulas. From the time Abbott restarts the site, it will take six to eight weeks before product is available on shelves.’